Roundtable Roundup: Relapsed CLL After 2 Prior Lines
In separate, live virtual events, Alvaro Jose Alencar, MD, and Michael E. Williams, MD, discussed third-line options for a patient with relapsed/refractory chronic lymphocytic leukemia (CLL).
- CASE SUMMARY
- A 65-year-old man who was diagnosed with CLL in 2019 presented to his oncologist at routine follow-up.
- Medical history: type 2 diabetes controlled with insulin
- Patient received previous treatments with:
- First line: acalabrutinib (Calquence) monotherapy
- Achieved good clinical response over 3 years but later progressed on therapy
- Second line: venetoclax (Venclexta) plus rituximab (Rituxan)
- Completed 24-month treatment regimen
- Was in treatment-free interval for 6 months
- Due to disease progression, his hemoglobin has dropped over the past 3 months and is currently at 10 g/dL.
- At follow-up, the patient is now aged 70 years and does not report any symptoms yet.
- ECOG performance status: 0
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
